Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma
Pre-treatment immune profiles may help predict which patients benefit most from advanced cell therapy, a hypothesis worth testing in larger studies.
In this small exploratory cohort (n=33) of CD19/CD22 bispecific CAR-T recipients, baseline immune composition — particularly CD4/CD8 ratio and naive T cell abundance — associated with distinct expansion trajectories and progression-free survival, generating a hypothesis that pre-infusion immune profiling may predict CAR-T outcomes. Authors appropriately flag findings as hypothesis-generating only, requiring validation in larger prospective cohorts.
What the study was
- Study design
- Retrospective exploratory; n=33 R/R LBCL patients receiving CD19/CD22 bispecific CAR-T; group-based trajectory modeling (GBTM); Kaplan-Meier + Cox regression; 22/33 received PD-1 inhibitor maintenance
- Population
- Adults with relapsed/refractory large B-cell lymphoma receiving CAR2219 (CD19/CD22 bispecific) CAR-T therapy
- Sample size
- 33
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Journal of Translational Medicine
Why it surfaced
Small but scientifically sound exploratory study of baseline immune predictors of CAR-T outcomes. Authors transparent about hypothesis-generating nature. CD4/CD8 ratio PFS association (HR 0.41) warrants prospective study. Score limited by n=33 and retrospective design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.